Winearls C G, Fabre J W, Millard P R, Morris P J
Clin Exp Immunol. 1979 Feb;35(2):242-9.
Cyclophosphamide and antilymphocyte serum (ALS) were compared for their ability to suppress renal allograft rejection in the rat. These two agents were chosen since they are generally considered to act on different arms of the immune response, and might therefore complement each other's action. Dose response studies showed that both agents could suppress rejection completely. There were no differences in their ability to suppress the lymphocytotoxic antibody response to the graft and the histological patterns of rejection were similar. There was no evidence that cyclo-phosphamide was more effective in suppressing vascular lesions. The doses of both agents which suppressed the lymphocytotoxic antibody response were substantially lower than those required to suppress graft rejection. When suboptimal doses of the two agents were administered together, the combinations were found to be additive and not synergistic.
比较了环磷酰胺和抗淋巴细胞血清（ALS）在大鼠中抑制肾移植排斥反应的能力。选择这两种药物是因为它们通常被认为作用于免疫反应的不同环节，因此可能相互补充作用。剂量反应研究表明，两种药物都能完全抑制排斥反应。它们在抑制对移植物的淋巴细胞毒性抗体反应的能力上没有差异，排斥反应的组织学模式相似。没有证据表明环磷酰胺在抑制血管病变方面更有效。抑制淋巴细胞毒性抗体反应的两种药物剂量均大大低于抑制移植物排斥反应所需的剂量。当一起给予次优剂量的两种药物时，发现组合是相加的而非协同的。
